CYDY CytoDyn

CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries

CytoDyn to Hold Webcast on January 6 to Provide Timelines for Clinical and Regulatory Developments, Submission of 4 HIV BLAs and EUA Requests for COVID in Different Countries

VANCOUVER, Washington, Dec. 29, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer, will host an investment community webcast on Wednesday, January 6, 2021.

Management will provide an update on recent clinical and regulatory developments regarding COVID-19 clinical trials, along with other strategic priorities:

1) BLA submissions to Health Canada, MHRA, EMA, and US FDA

2) HIV prevention trial/monotherapy trial

3) Potential revenue from HIV and manufacturing forecast

4) HIV Cure - amfAR

5) EUA submission timelines to same four agencies for COVID-19

6) Long-hauler clinical trial and potential data readout timelines

7) NASH trial and potential interim analysis timeline

8) Cancer trial Breakthrough Therapy designation potential timelines

9) GvHD trial status

10) Stroke/MS new trials in 2021

11) NASDAQ uplisting status

Management will also provide approximately 30-45 minutes to address questions submitted online by analysts and investors.

Date: Wednesday, January 6, 2021

Time: 1:00 pm PT / 4:00 pm ET

Dial-In: None.

Questions:

  • Prior to the webcast, questions can be submitted online to
  • During the webcast, questions can be submitted through the webcast link below.

This is a “listen only” webcast, which can be accessed via CytoDyn’s corporate website at  under the Investors section/IR Calendar and will be archived for 30 days. Participants are encouraged to go to the website 15 minutes prior to the start of the webcast to register, download and install any necessary software. The webcast can also be accessed via the following link:

The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until February 6, 2021.

CONTACTS

Investors:

Michael Mulholland

Office: 360.980.8524, ext. 102



EN
30/12/2020

Underlying

CYDYCytoDyn

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CytoDyn

 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn Secures $30 Million Commitment from Yorkville Advisors

CytoDyn Secures $30 Million Commitment from Yorkville Advisors VANCOUVER, Washington, Nov. 03, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has secured a $30 million funding commitment from Yorkville Advisors Global. Under the terms of the agreement, CytoDyn...

November 3, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference CFO Robert E. Hoffman to deliver company presentation on October 21, 2025 VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), announced that CFO Robert E. Hoffman will present a corporate...

October 9, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

September 2025 Letter to Shareholders

September 2025 Letter to Shareholders VANCOUVER, Washington, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As this pivotal year continues to take shape for CytoDyn Inc. (“CytoDyn” or the “Company”), I am pleased to share the progress we have made in advancing leronlimab as an innovative treatment in oncology. We remain confident that addressing critical unmet needs in this field is the best way to build value while improving the lives of patients. The foundation of our conviction in leronlimab rests on both preclinical and clinical evidence. From laboratory insights to encourag...

September 30, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpo...

CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclona...

September 25, 2025 1 EN
 PRESS RELEASE
Free
CYDY CYTODYN

CytoDyn to Present at the AACR Special Conference: Mechanisms of Cance...

CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced it has been selected for a poster and an oral presentation at the upcoming A...

September 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch